FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022389605> ?p ?o ?g. }

• W2022389605 endingPage "2135" @default.
• W2022389605 startingPage "2133" @default.
• W2022389605 abstract "Incretin-based therapies, principally glucagon-like peptide-1 receptor (GLP-1R) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors, have slowly gained traction in the therapy of type 2 diabetes. DPP-4 inhibitors, which exert their activities through potentiation of endogenous GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) action (1), are well tolerated and may be combined with multiple oral agents, making them well suited for use at multiple stages in the treatment of type 2 diabetes. GLP-1R agonists require injection, and are less well tolerated due principally to gastrointestinal adverse events (nausea, and less commonly diarrhea and vomiting). Hence, like insulin, they are frequently considered for use in patients who have failed to achieve adequate glycemic control on one or more oral agents alone. However, long-acting GLP-1R agonists are more potent glucose-lowering agents compared with DPP-4 inhibitors (2), and they may produce weight loss, two major points of differentiation with meaningful clinical impact.As the field of incretin biology gained prominence after clinical observations describing the importance of gut-derived factors in the potentiation of glucose-dependent insulin secretion, it is not surprising that the β-cell continues to be viewed as the predominant target of incretin action. Indeed, both GLP-1 and GIP robustly potentiate glucose-dependent insulin secretion in nondiabetic human subjects, and GLP-1 restores or enhances β-cell glucose sensing and insulin secretion even in diabetic patients with considerable loss of β-cell responsivity to glucose or sulfonylureas. Both GLP-1 and GIP also exhibit robust proliferative and antiapoptotic actions on rodent β-cells in experimental models of type 2 diabetes (3), and GLP-1 exerts salutary effects on the molecular mechanisms underlying β-cell function and enhances β-cell survival in studies with human islets cultured ex vivo (4,5). Hence, there has been considerable anticipation that incretin-based therapies may exert “disease-modifying” effects in type 2 diabetes through a combination of mechanisms including enhancing …" @default.
• W2022389605 created "2016-06-24" @default.
• W2022389605 creator A5057472647 @default.
• W2022389605 date "2011-08-25" @default.
• W2022389605 modified "2023-10-18" @default.
• W2022389605 title "Incretin-Based Therapy and the Quest for Sustained Improvements in β-Cell Health" @default.
• W2022389605 cites W1987538170 @default.
• W2022389605 cites W2016565181 @default.
• W2022389605 cites W2029228033 @default.
• W2022389605 cites W2032322539 @default.
• W2022389605 cites W2054555039 @default.
• W2022389605 cites W2061627213 @default.
• W2022389605 cites W2075355954 @default.
• W2022389605 cites W2089443047 @default.
• W2022389605 cites W2101990128 @default.
• W2022389605 cites W2107076497 @default.
• W2022389605 cites W2107949845 @default.
• W2022389605 cites W2113367996 @default.
• W2022389605 cites W2134760433 @default.
• W2022389605 cites W2146333376 @default.
• W2022389605 cites W2148798434 @default.
• W2022389605 cites W2152956628 @default.
• W2022389605 cites W2163146250 @default.
• W2022389605 cites W2171779326 @default.
• W2022389605 cites W2117469918 @default.
• W2022389605 doi "https://doi.org/10.2337/dc11-0986" @default.
• W2022389605 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3161285" @default.
• W2022389605 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21868783" @default.
• W2022389605 hasPublicationYear "2011" @default.
• W2022389605 type Work @default.
• W2022389605 sameAs 2022389605 @default.
• W2022389605 citedByCount "20" @default.
• W2022389605 countsByYear W20223896052013 @default.
• W2022389605 countsByYear W20223896052014 @default.
• W2022389605 countsByYear W20223896052015 @default.
• W2022389605 countsByYear W20223896052016 @default.
• W2022389605 countsByYear W20223896052017 @default.
• W2022389605 countsByYear W20223896052018 @default.
• W2022389605 countsByYear W20223896052022 @default.
• W2022389605 crossrefType "journal-article" @default.
• W2022389605 hasAuthorship W2022389605A5057472647 @default.
• W2022389605 hasBestOaLocation W20223896051 @default.
• W2022389605 hasConcept C126322002 @default.
• W2022389605 hasConcept C134018914 @default.
• W2022389605 hasConcept C177713679 @default.
• W2022389605 hasConcept C2777180221 @default.
• W2022389605 hasConcept C2778881409 @default.
• W2022389605 hasConcept C555293320 @default.
• W2022389605 hasConcept C71924100 @default.
• W2022389605 hasConceptScore W2022389605C126322002 @default.
• W2022389605 hasConceptScore W2022389605C134018914 @default.
• W2022389605 hasConceptScore W2022389605C177713679 @default.
• W2022389605 hasConceptScore W2022389605C2777180221 @default.
• W2022389605 hasConceptScore W2022389605C2778881409 @default.
• W2022389605 hasConceptScore W2022389605C555293320 @default.
• W2022389605 hasConceptScore W2022389605C71924100 @default.
• W2022389605 hasIssue "9" @default.
• W2022389605 hasLocation W20223896051 @default.
• W2022389605 hasLocation W20223896052 @default.
• W2022389605 hasLocation W20223896053 @default.
• W2022389605 hasLocation W20223896054 @default.
• W2022389605 hasOpenAccess W2022389605 @default.
• W2022389605 hasPrimaryLocation W20223896051 @default.
• W2022389605 hasRelatedWork W1563850031 @default.
• W2022389605 hasRelatedWork W1977226383 @default.
• W2022389605 hasRelatedWork W2079980094 @default.
• W2022389605 hasRelatedWork W2094113608 @default.
• W2022389605 hasRelatedWork W2152600766 @default.
• W2022389605 hasRelatedWork W2233866314 @default.
• W2022389605 hasRelatedWork W2383009242 @default.
• W2022389605 hasRelatedWork W2415759662 @default.
• W2022389605 hasRelatedWork W2743174471 @default.
• W2022389605 hasRelatedWork W3036934084 @default.
• W2022389605 hasVolume "34" @default.
• W2022389605 isParatext "false" @default.
• W2022389605 isRetracted "false" @default.
• W2022389605 magId "2022389605" @default.
• W2022389605 workType "article" @default.